Aberdeen Group plc Sells 249,355 Shares of Insulet Corporation $PODD

Insulet logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Aberdeen Group cut its Insulet stake by 86.6% in the third quarter, selling 249,355 shares and retaining 38,485 shares valued at about $5.0 million.
  • Insulet reported quarterly EPS of $1.99, beating the $1.59 consensus, while revenue rose 19.2% year over year to $842 million.
  • Analysts’ consensus rating was Hold, with an average price target of $185.04; shares opened at $137.23, well below their 200-day moving average of $171.25.
  • Interested in Insulet? Here are five stocks we like better.

Aberdeen Group plc lessened its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 86.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 38,485 shares of the medical instruments supplier's stock after selling 249,355 shares during the period. Aberdeen Group plc owned about 0.06% of Insulet worth $5,021,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of PODD. Allworth Financial LP grew its stake in Insulet by 2.3% during the 3rd quarter. Allworth Financial LP now owns 3,104 shares of the medical instruments supplier's stock valued at $405,000 after acquiring an additional 71 shares in the last quarter. Fifth Third Bancorp lifted its position in shares of Insulet by 21.3% in the third quarter. Fifth Third Bancorp now owns 64,540 shares of the medical instruments supplier's stock worth $8,421,000 after purchasing an additional 11,334 shares in the last quarter. Maryland State Retirement & Pension System lifted its position in shares of Insulet by 22.5% in the third quarter. Maryland State Retirement & Pension System now owns 4,176 shares of the medical instruments supplier's stock worth $545,000 after purchasing an additional 768 shares in the last quarter. Ritholtz Wealth Management purchased a new stake in shares of Insulet in the third quarter worth approximately $276,000. Finally, Jacobi Capital Management LLC acquired a new stake in shares of Insulet during the third quarter worth approximately $40,000.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on PODD. Robert W. Baird set a $175.00 price objective on shares of Insulet in a research report on Thursday, August 6th. Wall Street Zen upgraded shares of Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, November 7th. Oppenheimer lowered shares of Insulet from an "outperform" rating to a "market perform" rating in a research note on Wednesday, August 5th. Citigroup upped their price target on shares of Insulet from $150.00 to $170.00 and gave the stock a "neutral" rating in a research note on Thursday, November 5th. Finally, Truist Financial reissued a "hold" rating and set a $160.00 price objective (up from $153.00) on shares of Insulet in a research report on Monday, November 9th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $185.04.

Get Our Latest Stock Analysis on PODD

Insulet Stock Performance

Shares of PODD opened at $137.23 on Friday. The company's fifty day moving average is $142.25 and its 200-day moving average is $171.25. Insulet Corporation has a 12 month low of $126.40 and a 12 month high of $354.88. The firm has a market cap of $9.52 billion, a price-to-earnings ratio of 22.35, a price-to-earnings-growth ratio of 1.07 and a beta of 1.06. The company has a quick ratio of 1.83, a current ratio of 2.51 and a debt-to-equity ratio of 0.60.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.59 by $0.40. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The business had revenue of $842.00 million during the quarter, compared to analyst estimates of $832.63 million. During the same quarter in the previous year, the business earned $1.24 EPS. Insulet's quarterly revenue was up 19.2% compared to the same quarter last year. Equities analysts expect that Insulet Corporation will post 6.76 EPS for the current fiscal year.

About Insulet

(Free Report)

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.

Featured Stories

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Insulet Right Now?

Before you consider Insulet, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.

While Insulet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines